D-1101-2020 Class II Ongoing
FDA drug recall D-1101-2020 was initiated by Teva Pharmaceuticals USA on Mar 25, 2020 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 15, 2020
- Initiation Date
- Mar 25, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
LOSARTAN POTASSIUM TABLETS, USP 50 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia, Malta NDC 0591-3746-00
Reason for recall
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Distribution pattern
Bulk product was distributed to one re-packager in California.
Code information
Lots 1195625A, 1195624A, 1195623A, exp. date 03/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1101-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026